JP2014511361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511361A5 JP2014511361A5 JP2013550891A JP2013550891A JP2014511361A5 JP 2014511361 A5 JP2014511361 A5 JP 2014511361A5 JP 2013550891 A JP2013550891 A JP 2013550891A JP 2013550891 A JP2013550891 A JP 2013550891A JP 2014511361 A5 JP2014511361 A5 JP 2014511361A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- pharmaceutical composition
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305089A EP2481758A1 (en) | 2011-01-28 | 2011-01-28 | Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566) |
| EP11305088.4 | 2011-01-28 | ||
| EP11305088.4A EP2650016A1 (en) | 2011-01-28 | 2011-01-28 | Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565) |
| EP11305089.2 | 2011-01-28 | ||
| EP11305514 | 2011-04-29 | ||
| EP11305513 | 2011-04-29 | ||
| EP11305514.9 | 2011-04-29 | ||
| EP11305513.1 | 2011-04-29 | ||
| EP11306040 | 2011-08-12 | ||
| EP11306039 | 2011-08-12 | ||
| EP11306039.6 | 2011-08-12 | ||
| EP11306040.4 | 2011-08-12 | ||
| EP11306202 | 2011-09-22 | ||
| EP11306201.2 | 2011-09-22 | ||
| EP11306202.0 | 2011-09-22 | ||
| EP11306201 | 2011-09-22 | ||
| EP11306449 | 2011-11-08 | ||
| EP11306449.7 | 2011-11-08 | ||
| EP11306450.5 | 2011-11-08 | ||
| EP11306450 | 2011-11-08 | ||
| PCT/EP2012/051320 WO2012101252A2 (en) | 2011-01-28 | 2012-01-27 | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000849A Division JP2017095490A (ja) | 2011-01-28 | 2017-01-06 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511361A JP2014511361A (ja) | 2014-05-15 |
| JP2014511361A5 true JP2014511361A5 (enExample) | 2015-03-19 |
| JP6375113B2 JP6375113B2 (ja) | 2018-08-15 |
Family
ID=45529125
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550891A Active JP6375113B2 (ja) | 2011-01-28 | 2012-01-27 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2013550892A Pending JP2014508142A (ja) | 2011-01-28 | 2012-01-27 | Ｐｃｓｋ９に対するヒト抗体を含んでなる医薬組成物 |
| JP2017000850A Pending JP2017095491A (ja) | 2011-01-28 | 2017-01-06 | Ｐｃｓｋ９に対するヒト抗体を含んでなる医薬組成物 |
| JP2017000849A Pending JP2017095490A (ja) | 2011-01-28 | 2017-01-06 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2018168406A Active JP6730388B2 (ja) | 2011-01-28 | 2018-09-10 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2020114604A Active JP7140800B2 (ja) | 2011-01-28 | 2020-07-02 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2022116860A Pending JP2022141869A (ja) | 2011-01-28 | 2022-07-22 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2024112158A Pending JP2024138473A (ja) | 2011-01-28 | 2024-07-12 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550892A Pending JP2014508142A (ja) | 2011-01-28 | 2012-01-27 | Ｐｃｓｋ９に対するヒト抗体を含んでなる医薬組成物 |
| JP2017000850A Pending JP2017095491A (ja) | 2011-01-28 | 2017-01-06 | Ｐｃｓｋ９に対するヒト抗体を含んでなる医薬組成物 |
| JP2017000849A Pending JP2017095490A (ja) | 2011-01-28 | 2017-01-06 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2018168406A Active JP6730388B2 (ja) | 2011-01-28 | 2018-09-10 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2020114604A Active JP7140800B2 (ja) | 2011-01-28 | 2020-07-02 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2022116860A Pending JP2022141869A (ja) | 2011-01-28 | 2022-07-22 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
| JP2024112158A Pending JP2024138473A (ja) | 2011-01-28 | 2024-07-12 | 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体 |
Country Status (37)
Families Citing this family (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| CA2840482C (en) * | 2011-07-14 | 2018-10-16 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| JP2015530867A (ja) | 2012-06-15 | 2015-10-29 | ジェネンテック， インコーポレイテッド | 抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法 |
| TWI596115B (zh) * | 2012-08-13 | 2017-08-21 | 再生元醫藥公司 | 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體 |
| EP2703008A1 (en) * | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
| EP2703009A1 (en) * | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EP2922590B1 (en) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Drug delivery device |
| TWI614041B (zh) | 2013-03-15 | 2018-02-11 | 安美基公司 | 用於注射器之匣盒 |
| US10092703B2 (en) | 2013-03-15 | 2018-10-09 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| SG11201507417RA (en) | 2013-03-15 | 2015-10-29 | Amgen Inc | Body contour adaptable autoinjector device |
| EP2976117B1 (en) | 2013-03-22 | 2020-12-30 | Amgen Inc. | Injector and method of assembly |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EP2810955A1 (en) * | 2013-06-07 | 2014-12-10 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| EP2862877A1 (en) * | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| TW202021614A (zh) * | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| ES2901400T3 (es) * | 2013-06-07 | 2022-03-22 | Regeneron Pharma | Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9 |
| WO2014209384A1 (en) * | 2013-06-28 | 2014-12-31 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolema |
| WO2015050158A1 (ja) * | 2013-10-01 | 2015-04-09 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン |
| ES2779126T3 (es) * | 2013-10-11 | 2020-08-13 | Sanofi Biotechnology | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia |
| EP3689913B1 (en) * | 2013-10-11 | 2022-03-23 | Sanofi Biotechnology | Use of a pcsk9 inhibitor to treat hyperlipidemia |
| EP3957345B1 (en) | 2013-10-24 | 2025-12-10 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
| CA2920894C (en) | 2013-10-24 | 2023-03-14 | Amgen Inc. | Injector and method of assembly |
| US10428157B2 (en) * | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| DE112014005747T5 (de) * | 2013-12-17 | 2016-10-06 | Kymab Limited | Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| WO2015123423A2 (en) * | 2014-02-14 | 2015-08-20 | Regeneron Pharmaceuticals, Inc | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN114642661A (zh) * | 2014-03-17 | 2022-06-21 | 赛诺菲生物技术公司 | 用于降低心血管风险的方法 |
| US20150283236A1 (en) * | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
| US10872313B2 (en) | 2015-06-02 | 2020-12-22 | ROCA Medical Ltd. | Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy |
| MX388536B (es) | 2014-05-07 | 2025-03-20 | Amgen Inc | Autoinyector con elementos reductores del shock. |
| CN106470717B (zh) | 2014-06-03 | 2020-09-11 | 安姆根有限公司 | 药物递送系统和使用方法 |
| MX2017000527A (es) * | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| KR20230074283A (ko) * | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| EP3169362B1 (en) * | 2014-07-16 | 2020-06-10 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| AU2015332557B2 (en) | 2014-10-14 | 2020-05-14 | Amgen Inc. | Drug injection device with visual and audio indicators |
| ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
| EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
| CA3069716C (en) | 2015-02-17 | 2021-11-09 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
| MX384944B (es) | 2015-03-20 | 2025-03-14 | Univ Aarhus | Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". |
| CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
| US10548974B2 (en) * | 2015-06-02 | 2020-02-04 | ROCA Medical Ltd. | Therapeutic treatment kit for allergies based on DNA profiles |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| CN105348390B (zh) * | 2015-10-26 | 2018-08-28 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
| WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
| BR112018013256A2 (pt) | 2015-12-31 | 2018-12-11 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo |
| EP3401336A4 (en) | 2016-01-05 | 2020-01-22 | Jiangsu Hengrui Medicine Co., Ltd. | ANTI-PCSK9 ANTIBODIES, ASSOCIATED ANTIGEN BINDING FRAGMENT, AND ASSOCIATED MEDICAL APPLICATION |
| US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
| WO2017138557A1 (ja) | 2016-02-08 | 2017-08-17 | 国立大学法人三重大学 | 免疫チェックポイント阻害剤抵抗性腫瘍に対するｔ細胞輸注療法の前処置薬 |
| WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| AU2017263558B2 (en) | 2016-05-13 | 2022-12-22 | Amgen Inc. | Vial sleeve assembly |
| EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| US20190240316A1 (en) * | 2016-10-17 | 2019-08-08 | Vanderbilt University | Human respiratory syncytial virus antibodies and methods of use therefor |
| WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
| EP3582829A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Insertion mechanism for drug delivery device |
| MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
| EP3592403B1 (en) | 2017-03-06 | 2025-08-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
| CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
| AU2018230486B2 (en) | 2017-03-09 | 2023-05-11 | Amgen Inc. | Insertion mechanism for drug delivery device |
| CN118743804A (zh) | 2017-03-28 | 2024-10-08 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
| KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
| AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
| AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
| MA49461A (fr) | 2017-06-23 | 2020-04-29 | Amgen Inc | Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur |
| MA49562A (fr) | 2017-07-14 | 2020-05-20 | Amgen Inc | Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion |
| US11672733B2 (en) | 2017-07-21 | 2023-06-13 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
| JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
| US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
| WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
| WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| ES2939292T3 (es) | 2017-10-04 | 2023-04-20 | Amgen Inc | Adaptador de flujo para dispositivo de administración de fármacos |
| EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
| EP3694578B1 (en) | 2017-10-09 | 2025-09-24 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
| US12053618B2 (en) | 2017-11-06 | 2024-08-06 | Amgen Inc. | Fill-finish assemblies and related methods |
| WO2019089178A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
| IL319987A (en) | 2017-11-10 | 2025-06-01 | Amgen Inc | Plungers for drug delivery devices |
| JP7747438B2 (ja) | 2017-11-16 | 2025-10-01 | アムジエン・インコーポレーテツド | 失速及び終点検出を有するオートインジェクタ |
| SG11202003004RA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Door latch mechanism for drug delivery device |
| JP6639463B2 (ja) * | 2017-12-21 | 2020-02-05 | アムジエン・インコーポレーテツド | ホモ接合性家族性高コレステロール血症の治療方法 |
| AU2019231703A1 (en) * | 2018-03-06 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Use of PCSK9 inhibitor for reducing cardiovascular risk |
| EP3793612A4 (en) * | 2018-05-16 | 2022-03-02 | LIB Therapeutics, LLC | COMPOSITIONS CONTAINING PCSK9 BINDING MOLECULES AND METHODS OF USE |
| CN112512480B (zh) * | 2018-05-21 | 2024-10-01 | 中外制药株式会社 | 被封入玻璃容器的冷冻干燥制剂 |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| US12115360B2 (en) | 2018-07-24 | 2024-10-15 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| US12303677B2 (en) | 2018-07-24 | 2025-05-20 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
| MX2021000749A (es) | 2018-07-24 | 2021-03-29 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
| US12042645B2 (en) | 2018-07-24 | 2024-07-23 | Amgen Inc. | Delivery devices for administering drugs |
| EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| US20210346601A1 (en) | 2018-09-24 | 2021-11-11 | Amgen Inc. | Interventional dosing systems and methods |
| EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| AU2019352616B2 (en) | 2018-10-02 | 2024-10-10 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| US12151089B2 (en) | 2018-10-05 | 2024-11-26 | Amgen Inc. | Drug delivery device having dose indicator |
| JP2022504805A (ja) | 2018-10-15 | 2022-01-13 | アムジエン・インコーポレーテツド | 薬物送達デバイスのプラットフォーム式組み立てプロセス |
| SG11202103800RA (en) | 2018-10-15 | 2021-05-28 | Amgen Inc | Drug delivery device having damping mechanism |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| AU2019370159B2 (en) | 2018-11-01 | 2025-05-29 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| RS66416B1 (sr) | 2019-01-18 | 2025-02-28 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene |
| EP3923896A1 (en) * | 2019-02-12 | 2021-12-22 | Amgen Inc. | Systems and approaches for drug delivery device reconstitution |
| JP7510952B2 (ja) | 2019-04-24 | 2024-07-04 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
| CA3139943A1 (en) | 2019-05-17 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| JP7608439B2 (ja) | 2019-08-23 | 2025-01-06 | アムジエン・インコーポレーテツド | 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法 |
| CA3153518A1 (en) * | 2019-10-18 | 2021-04-22 | Amgen Inc. | Systems and approaches for drug delivery device reconstitution |
| JP2021041262A (ja) * | 2020-12-17 | 2021-03-18 | 株式会社三洋物産 | 遊技機 |
| CA3217207A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
| WO2026030152A1 (en) | 2024-07-29 | 2026-02-05 | Amgen Inc. | System and method for assessing transferability of a fill recipe |
Family Cites Families (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| ES2134212T3 (es) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| DE69333928T2 (de) | 1992-04-30 | 2006-08-17 | Probitas Pharma Inc., Los Angeles | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes |
| EP0672144A1 (en) | 1992-10-20 | 1995-09-20 | Chiron Corporation | Interleukin-6 receptor antagonists |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| WO1996012503A1 (en) | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remedy for diseases caused by il-6 production |
| JP4079461B2 (ja) | 1994-12-29 | 2008-04-23 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを含んでなる抗腫瘍剤の作用増強剤 |
| CA2211578C (en) | 1995-02-13 | 2010-09-21 | Chugai Seiyaku Kabushiki Kaisha | Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| JP2000509018A (ja) | 1996-03-26 | 2000-07-18 | イーライ・リリー・アンド・カンパニー | 肥満タンパク質製剤 |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| DE69735888T2 (de) | 1996-06-27 | 2006-11-02 | Chugai Seiyaku K.K. | Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoffsenfgasen verwendet werden kann |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| WO1999038495A2 (en) | 1998-01-30 | 1999-08-05 | Scios Inc. | Controlled release delivery of peptide or protein |
| HU225539B1 (en) | 1998-03-17 | 2007-02-28 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US7129338B1 (en) | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
| EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
| US7029895B2 (en) | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
| ATE316531T1 (de) | 1999-10-07 | 2006-02-15 | Lilly Co Eli | Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1 |
| CA2399727A1 (en) | 2000-02-07 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Narc-1, subtilase-like homologs |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| WO2002020767A2 (en) | 2000-09-08 | 2002-03-14 | Massachusetts Institute Of Technology | G-csf analog compositions and methods |
| PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| AU2002210952B2 (en) | 2000-10-25 | 2007-01-11 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist |
| JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| DE10355251A1 (de) | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| WO2005080429A2 (en) | 2004-02-11 | 2005-09-01 | Warner-Lambert Company Llc | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| EP2399936A3 (en) | 2004-07-26 | 2012-02-22 | Biogen Idec MA Inc. | Anti-CD154 antibodies |
| US20110313024A1 (en) | 2004-08-20 | 2011-12-22 | Leonid Beigelman | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1828250A2 (en) | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
| US20060147945A1 (en) | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
| JP2009516692A (ja) | 2005-11-22 | 2009-04-23 | ワイス | 免疫グロブリン融合タンパク質製剤 |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| ES2366973T3 (es) | 2006-05-05 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimiento para modular la expresión génica. |
| CA3044969A1 (en) | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| EP2194128B1 (en) | 2006-05-11 | 2012-08-01 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| EP3753548A1 (en) | 2006-06-16 | 2020-12-23 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CA2667989A1 (en) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonists of pcsk9 |
| EP2083861A4 (en) | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
| WO2008057457A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| WO2008057458A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| EP2453016A1 (en) | 2006-11-27 | 2012-05-16 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CN101589143A (zh) | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
| JP5100101B2 (ja) | 2006-12-12 | 2012-12-19 | キヤノン株式会社 | 画像形成装置 |
| WO2008125623A2 (en) | 2007-04-13 | 2008-10-23 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| CA2686238C (en) | 2007-05-15 | 2018-09-25 | F. Hoffmann-La Roche Ag | Metabotropic glutamate receptor 7(mglur7)-binding antibody |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20100286021A1 (en) | 2007-09-25 | 2010-11-11 | Qun-Yong Zhou | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders |
| WO2009041621A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗il-6レセプター抗体 |
| SG2013014352A (en) * | 2007-10-26 | 2014-09-26 | Merck Sharp & Dohme | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| TWI700293B (zh) | 2008-04-11 | 2020-08-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗體 |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| TR201802935T4 (tr) | 2008-09-19 | 2018-03-21 | Pfizer | Stabil sıvı antikor formülasyonu. |
| KR20140019035A (ko) | 2008-09-19 | 2014-02-13 | 에프. 호프만-라 로슈 아게 | 신규한 항체 제형 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010068526A1 (en) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| US20100216667A1 (en) | 2008-12-17 | 2010-08-26 | Meyer Brian K | Method for determining compatibility of an active pharmaceutical ingredient with materials |
| AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| KR20120050429A (ko) | 2009-06-15 | 2012-05-18 | 알닐람 파마슈티칼스 인코포레이티드 | Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ |
| CN102695499A (zh) | 2009-06-18 | 2012-09-26 | 惠氏有限责任公司 | 小模块免疫药物的冻干制剂 |
| US20110009628A1 (en) | 2009-07-08 | 2011-01-13 | Haiyan Liu | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same |
| EP2456870A1 (en) | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| WO2011028938A1 (en) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| WO2011037791A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
| WO2011039578A1 (en) | 2009-10-02 | 2011-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event |
| EP2493507A4 (en) | 2009-10-30 | 2013-11-20 | Merck Sharp & Dohme | AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF |
| WO2011053759A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax1 and ax189 pcsk9 antagonists and variants |
| PT3721904T (pt) | 2009-11-20 | 2021-11-15 | Biocon Ltd | Formulações de anticorpo t1h |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| EP2545079A2 (en) | 2010-03-11 | 2013-01-16 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| DE102010024698A1 (de) | 2010-06-23 | 2011-12-29 | Eads Deutschland Gmbh | Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs |
| WO2012044999A2 (en) | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| PL2624865T3 (pl) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
| WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| CA2817015A1 (en) * | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| CA2820953A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
| BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| CN103562227B (zh) | 2011-02-11 | 2016-12-21 | 诺瓦提斯公司 | Pcsk9拮抗剂 |
| US8440890B1 (en) | 2011-03-09 | 2013-05-14 | Pioneer Hi Bred International Inc | Maize variety inbred PH1D0D |
| TR201905991T4 (tr) | 2011-04-20 | 2019-05-21 | Amgen Inc | Oto enjektör aparatı. |
| AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
| US10040855B2 (en) | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| US20140004122A1 (en) | 2011-05-10 | 2014-01-02 | Amgen Inc. | Methods for treating or preventing cholesterol related disorders |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| CA2746171C (en) | 2011-07-13 | 2018-11-06 | William Jani | Retrievable stimulation frac (rsf) plug |
| CA2840482C (en) | 2011-07-14 | 2018-10-16 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| MX351148B (es) | 2012-03-08 | 2017-10-04 | Hoffmann La Roche | Formulacion de anticuerpo beta amiloide. |
| US9663825B2 (en) | 2012-04-19 | 2017-05-30 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2854787A4 (en) | 2012-05-25 | 2016-02-24 | Catabasis Pharmaceuticals Inc | METHODS OF DECREASING PROPANTEIN CONVERTASE SUBTILISINE / KEXINE TYPE 9 (PCSK9) |
| TWI596115B (zh) | 2012-08-13 | 2017-08-21 | 再生元醫藥公司 | 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體 |
| EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EP2703008A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
| EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| RU2538801C2 (ru) | 2013-02-07 | 2015-01-10 | Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" | ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
| TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| EP3689913B1 (en) | 2013-10-11 | 2022-03-23 | Sanofi Biotechnology | Use of a pcsk9 inhibitor to treat hyperlipidemia |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| WO2015123423A2 (en) * | 2014-02-14 | 2015-08-20 | Regeneron Pharmaceuticals, Inc | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy |
| US20150283236A1 (en) | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
| CN114642661A (zh) | 2014-03-17 | 2022-06-21 | 赛诺菲生物技术公司 | 用于降低心血管风险的方法 |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| EP3169362B1 (en) | 2014-07-16 | 2020-06-10 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| US10933134B2 (en) | 2017-03-16 | 2021-03-02 | Memorial Sloan Kettering Cancer Center | Combination therapies for treatment of cancer |
| US20190031774A1 (en) | 2017-06-09 | 2019-01-31 | Sanofi Biotechnology | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
| TW202310872A (zh) | 2017-06-09 | 2023-03-16 | 法商賽諾菲生物技術公司 | 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法 |
| AU2019231703A1 (en) | 2018-03-06 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Use of PCSK9 inhibitor for reducing cardiovascular risk |
-
2012
- 2012-01-27 BR BR112013018740A patent/BR112013018740A2/pt not_active Application Discontinuation
- 2012-01-27 CA CA2825778A patent/CA2825778A1/en not_active Abandoned
- 2012-01-27 EP EP12701015.5A patent/EP2668211A1/en not_active Withdrawn
- 2012-01-27 KR KR1020227032979A patent/KR20220136466A/ko not_active Ceased
- 2012-01-27 SG SG2013056437A patent/SG192117A1/en unknown
- 2012-01-27 AR ARP120100274A patent/AR084937A1/es unknown
- 2012-01-27 ES ES18162658T patent/ES2882570T3/es active Active
- 2012-01-27 KR KR1020197015144A patent/KR20190062612A/ko not_active Withdrawn
- 2012-01-27 HR HRP20180959TT patent/HRP20180959T1/hr unknown
- 2012-01-27 WO PCT/EP2012/051318 patent/WO2012101251A1/en not_active Ceased
- 2012-01-27 KR KR1020137022847A patent/KR20140012075A/ko not_active Ceased
- 2012-01-27 HU HUE12701742A patent/HUE039258T2/hu unknown
- 2012-01-27 SG SG2013056445A patent/SG192118A1/en unknown
- 2012-01-27 WO PCT/EP2012/051320 patent/WO2012101252A2/en not_active Ceased
- 2012-01-27 RU RU2016142277A patent/RU2721279C2/ru active
- 2012-01-27 AR ARP120100275A patent/AR084938A1/es unknown
- 2012-01-27 PE PE2013001712A patent/PE20140372A1/es not_active Application Discontinuation
- 2012-01-27 CN CN2012800155711A patent/CN103476797A/zh active Pending
- 2012-01-27 EP EP17196008.1A patent/EP3326648B1/en active Active
- 2012-01-27 US US13/982,381 patent/US9682013B2/en active Active
- 2012-01-27 MX MX2018003358A patent/MX385311B/es unknown
- 2012-01-27 KR KR1020207033437A patent/KR20200133826A/ko not_active Ceased
- 2012-01-27 MY MYPI2017701720A patent/MY176600A/en unknown
- 2012-01-27 MX MX2017005594A patent/MX366458B/es unknown
- 2012-01-27 AR ARP120100276A patent/AR084939A1/es not_active Application Discontinuation
- 2012-01-27 MY MYPI2013002740A patent/MY165159A/en unknown
- 2012-01-27 PL PL12701742T patent/PL2668212T3/pl unknown
- 2012-01-27 CA CA2825838A patent/CA2825838C/en active Active
- 2012-01-27 JP JP2013550891A patent/JP6375113B2/ja active Active
- 2012-01-27 CN CN201910870270.0A patent/CN110711248A/zh active Pending
- 2012-01-27 DK DK12701742.4T patent/DK2668212T3/en active
- 2012-01-27 PT PT127017424T patent/PT2668212T/pt unknown
- 2012-01-27 EP EP12701742.4A patent/EP2668212B1/en active Active
- 2012-01-27 PH PH1/2013/501576A patent/PH12013501576A1/en unknown
- 2012-01-27 WO PCT/EP2012/051321 patent/WO2012101253A1/en not_active Ceased
- 2012-01-27 ES ES17196008T patent/ES2873273T3/es active Active
- 2012-01-27 JP JP2013550892A patent/JP2014508142A/ja active Pending
- 2012-01-27 PL PL18162658T patent/PL3395836T3/pl unknown
- 2012-01-27 US US13/982,373 patent/US9561155B2/en active Active
- 2012-01-27 EP EP18162658.1A patent/EP3395836B1/en active Active
- 2012-01-27 LT LTEP12701742.4T patent/LT2668212T/lt unknown
- 2012-01-27 AU AU2012210480A patent/AU2012210480B2/en active Active
- 2012-01-27 MX MX2013008669A patent/MX367075B/es active IP Right Grant
- 2012-01-27 BR BR112013018877A patent/BR112013018877A2/pt not_active Application Discontinuation
- 2012-01-27 AU AU2012210481A patent/AU2012210481B2/en active Active
- 2012-01-27 PH PH1/2013/501577A patent/PH12013501577A1/en unknown
- 2012-01-27 ES ES12701742.4T patent/ES2674600T3/es active Active
- 2012-01-27 PE PE2018000400A patent/PE20181052A1/es unknown
- 2012-01-27 RU RU2013139727/15A patent/RU2603481C2/ru active
- 2012-01-27 CN CN201711012165.0A patent/CN107899010A/zh active Pending
- 2012-01-27 MX MX2013008672A patent/MX347602B/es active IP Right Grant
- 2012-01-27 KR KR1020197021479A patent/KR20190090055A/ko not_active Ceased
- 2012-01-27 KR KR1020137022848A patent/KR20140006013A/ko not_active Ceased
- 2012-01-27 RU RU2013139736/15A patent/RU2604139C2/ru active
- 2012-01-27 RU RU2016142273A patent/RU2016142273A/ru not_active Application Discontinuation
- 2012-01-27 SI SI201231325T patent/SI2668212T1/en unknown
- 2012-01-27 PL PL17196008T patent/PL3326648T3/pl unknown
- 2012-01-27 RS RS20180725A patent/RS57339B1/sr unknown
- 2012-01-27 CN CN2012800154776A patent/CN103476796A/zh active Pending
- 2012-01-30 TW TW101102966A patent/TW201242613A/zh unknown
- 2012-01-30 TW TW101102967A patent/TWI625127B/zh active
- 2012-01-30 TW TW105117797A patent/TWI635870B/zh active
-
2013
- 2013-07-22 ZA ZA2013/05524A patent/ZA201305524B/en unknown
- 2013-07-23 ZA ZA2013/05565A patent/ZA201305565B/en unknown
- 2013-07-25 IL IL227657A patent/IL227657B/en active IP Right Grant
- 2013-07-25 IL IL227658A patent/IL227658A0/en active IP Right Grant
- 2013-07-26 NI NI201300064A patent/NI201300064A/es unknown
- 2013-07-26 CL CL2013002161A patent/CL2013002161A1/es unknown
- 2013-07-26 GT GT201300186A patent/GT201300186A/es unknown
- 2013-07-26 MX MX2019008245A patent/MX2019008245A/es unknown
- 2013-07-26 DO DO2013000170A patent/DOP2013000170A/es unknown
- 2013-07-26 EC ECSP13012792 patent/ECSP13012792A/es unknown
- 2013-07-26 CL CL2013002162A patent/CL2013002162A1/es unknown
- 2013-08-22 CR CR20130406A patent/CR20130406A/es unknown
- 2013-08-27 CO CO13203072A patent/CO6751276A2/es unknown
- 2013-08-27 MA MA36205A patent/MA34923B1/fr unknown
- 2013-08-27 CO CO13203075A patent/CO6751277A2/es unknown
-
2016
- 2016-12-22 US US15/389,130 patent/US20170266079A1/en not_active Abandoned
-
2017
- 2017-01-06 JP JP2017000850A patent/JP2017095491A/ja active Pending
- 2017-01-06 JP JP2017000849A patent/JP2017095490A/ja active Pending
- 2017-05-15 US US15/595,373 patent/US20170340515A1/en not_active Abandoned
- 2017-08-17 AU AU2017216547A patent/AU2017216547A1/en not_active Abandoned
- 2017-08-17 AU AU2017216546A patent/AU2017216546B2/en active Active
-
2018
- 2018-06-21 CY CY20181100645T patent/CY1121236T1/el unknown
- 2018-09-10 JP JP2018168406A patent/JP6730388B2/ja active Active
-
2019
- 2019-03-26 US US16/365,317 patent/US11246925B2/en active Active
- 2019-03-28 IL IL265707A patent/IL265707A/en unknown
- 2019-05-16 IL IL266682A patent/IL266682B/en active IP Right Grant
- 2019-09-11 AU AU2019229366A patent/AU2019229366B2/en active Active
-
2020
- 2020-07-02 JP JP2020114604A patent/JP7140800B2/ja active Active
-
2021
- 2021-02-24 PH PH12021500018A patent/PH12021500018A1/en unknown
- 2021-04-11 IL IL282219A patent/IL282219B/en unknown
- 2021-12-23 US US17/560,402 patent/US12083176B2/en active Active
-
2022
- 2022-07-22 JP JP2022116860A patent/JP2022141869A/ja active Pending
-
2024
- 2024-07-12 JP JP2024112158A patent/JP2024138473A/ja active Pending
- 2024-07-31 US US18/790,032 patent/US20250064926A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511361A5 (enExample) | ||
| JP2014508142A5 (enExample) | ||
| AU2020203636B2 (en) | Use of a PCSK9 inhibitor to treat hyperlipidemia | |
| ES2773111T3 (es) | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) | |
| US20230406957A1 (en) | Dosing regimens for use with pcsk9 inhibitors | |
| JP2020172514A5 (enExample) | ||
| RU2016142277A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| CN107922507B (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| AU2015217118A1 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| WO2021052472A1 (zh) | 抗pcsk9抗体用于预防或治疗胆固醇相关疾病的方法 | |
| HK40059806A (en) | Dosing regimens for use with pcsk9 inhibitors | |
| HK1227890B (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| HK1196834B (en) | INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LlPOPROTEIN(A) LEVELS | |
| HK1196834A (en) | INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LlPOPROTEIN(A) LEVELS | |
| NZ621135B2 (en) | METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |